EVERSANA builds its AI Agency with Estima acquisition
EVERSANA has acquired UK AI-powered health economics and outcomes research (HEOR) firm Estima to help its customers "modernise commercialisation."
Newsletters and Deep Dive digital magazine
EVERSANA has acquired UK AI-powered health economics and outcomes research (HEOR) firm Estima to help its customers "modernise commercialisation."
Merck KGaA has moved to streamline its focus with the sale of its contract development and manufacturing organisation (CDMO) business to Lonza.
The FDA has started its review of uniQure's gene therapy for neurodegenerative disorder Huntington's, but will require an advisory committee meeting.
Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test
Several years after its US approval, Ultragenyx's therapy for long-chain fatty acid oxidation disorders, Dojolvi, has been greenlit in the UK.
Editor's Picks
Newsletters and Deep Dive
digital magazine